| Literature DB >> 32531434 |
François Guérin1, Sabrine Lachaal2, Michel Auzou1, Cécile Le Brun3, Olivier Barraud4, Jean-Winoc Decousser5, Reto Lienhard6, Régine Baraduc7, Luc Dubreuil8, Vincent Cattoir9.
Abstract
Of 69 clinical isolates of Finegoldia magna tested, 36% presented high-level MICs of erythromycin (>256 μg/ml), harboring erm(A) (n = 20) or erm(B) (n=5). Of nine isolates exhibiting an inducible resistance phenotype to macrolides-lincosamides-streptogramins B, four (44%) were susceptible with a potential risk of treatment failure due to emergence of resistant mutants.Entities:
Keywords: F. magna; GPAC; MLS; anaerobes; clindamycin; erm(A); erm(B)
Mesh：
Substances：
Year: 2020 PMID： 32531434 DOI： 10.1016/j.anaerobe.2020.102220
Source DB: PubMed Journal: Anaerobe ISSN： 1075-9964 Impact factor: 3.331